Stage 0

1:12

Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, describes how the Oncotype DX DCIS Score is revolutionizing the way that DCIS breast cancer is being treated. Pathologists no longer have to rely on subjective assessments and can now examine individual breast cancer tumors to determine the aggressiveness.

5:09

In this video, Dr. Harness explains the reoccurrence rate for patients who are newly diagnosed with DCIS. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/#
 
Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask.
 
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.

0:57

The Oncotype DX DCIS Score is determined by examining a piece of breast cancer tumor tissue obtained at the time of surgery. Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, talks about how the test measures the levels of tumor-associated genes.

0:50

Patients diagnosed with DCIS breast cancer should talk to their surgeon or radiation oncologist about ordering the Oncotype DX DCIS Breast Cancer Assay so they can get a DCIS Score and determine the best treatment plan, according to Genomic Health's Senior Director of Pathology, Dr. Rick Baehner.

1:15

Dr. Rick Baehner, Senior Director of Pathology at Genomic Health, recounts a recent experience he had with a DCIS breast cancer patient.

1:32

Genomic Health Senior Director of Pathology Dr. Rick Baehner examines the benefits using the Oncotype DX DCIS Score over other tools that are currently being used to create DCIS breast cancer treatment decisions.

2:53

Not all DCIS patients will benefit from the addition of radiation therapy to their treatment. Genomic Health's Oncotype DX Breast Cancer Assay for DCIS patients provides a DCIS score from which breast cancer doctors and their patients can determine the appropriate personalized treatment plan.

1:03

Genomic Health's Dr. Rick Baehner, Senior Director of Pathology, reviews the various treatment options for those diagnosed with DCIS breast cancer. The Oncotype DX DCIS Breast Cancer Assay and DCIS Score only apply to those breast cancer patients who have a lumpectomy.

Advertisement